Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

ABSTRACT:

SUBMITTER: Davie A 

PROVIDER: S-EPMC10551672 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature